Marijuana has been Reclassified on the Federal Level – TacomaWeekly
The federal government’s announcement that marijuana will be reclassified from Schedule I to Schedule III under the Controlled Substances Act marks the most significant shift in U.S. cannabis policy in more than half a century. National headlines quickly labeled the move historic. In Washington State, however, and particularly in Pierce County, the practical impact is expected to be far less dramatic than the initial reaction suggests.
For local retailers, growers, patients, and advocates, the announcement raises a central question. How should people understand what this change actually does and does not do.
According to Catharine “Grandma Cat” Jeter, a longtime cannabis educator and activist who lives in Fircrest, expectations should be tempered.
“I do not anticipate meaningful changes for consumer sin the retail environments in the foreseeable future,” Jeter said. “The local laws that have regulated ahead of the federal government will continue to hold the keys to our immediate local future.”
Under the Controlled Substances Act, Schedule I substances are defined as having no accepted medical use and a high potential for abuse. Schedule III substances are recognized as having medical value and a lower potential for abuse than Schedule I or II drugs. The reclassification acknowledges what many states, including Washington, have operated under for years: that cannabis has medical applications. However, Schedule III does not legalize marijuana for consumers federally, nor does it override state regulatory systems.
“This is not descheduling,” Jeter said. “It is not plant freedom.”
Cannabis will remain within the federal drug control framework and subject to oversight by the Drug Enforcement Administration and potentially the Food and Drug Administration. For Washington’s cannabis market, which already operates under a complex regulatory structure, that distinction matters.
Washington’s system includes licensing caps, zoning restrictions, seed to sale tracking, and strict compliance rules. Those requirements are not expected to change as a result of the federal announcement.
“In the current Washington state production and retail context, there is little, if any, meaningful changeother than corporate taxation requirements,” Jeter said.
Retailers will continue to operate under Washington State Liquor and Cannabis Board rules. Possession limits remain in place. Home growing for non medical users remains illegal. Medical insurance coverage for herbal cannabis products does not change.
Where the federal shift may eventually have an impact is behind the scenes, particularly in taxation and research. One immediate potential benefit of Schedule III status is the elimination of Internal Revenue Code Section 280E. That provision prevents cannabis businesses from deducting ordinary business expenses because marijuana has been classified as a Schedule I substance.
“For growers and retailers, the most immediate impact is corporate taxation relief,” Jeter said.
That relief could improve financial stability in an industry that has faced falling prices, high compliance costs, and increasing consolidation. Still, Jeter cautioned that tax relief alone does not resolve the deeper challenges facing producers.
Looking forward, she expects research rather than recreational demand to begin shaping future product development.
“As research begins to gain traction, the ‘what’ of the product mix may begin to trend toward research generated products,” Jeter said. She added that there is likely to be continued skepticism in the medical community around THC as a therapeutic agent.
One of the federal government’s stated goals in rescheduling marijuana is to expand medical research, including human clinical trials that were previously difficult to conduct. According to Jeter, that assessment is accurate, but the implications are more complex than they appear.
“Schedule III allows for the human testing in the future that will create a basis for further regulation on human distribution products,” she said. “Yes, likely at retail drugstores.”
Historically, most peer reviewed cannabis research has taken place outside the United States, particularly in Israel and Western Europe. Federal restrictions made it difficult for American researchers to study cannabis in human trials, and the FDA regulates all studies involving human interaction with products. Schedule III opens the door for FDA regulated studies, but those studies require substantial financial investment.
That reality fuels concern among some advocates that pharmaceutical companies will be best positioned to benefit.
“Schedule III is the pharma company giveaway,” Jeter said. “It largely protects the plant for the pharmaceutical industry.”
While pharmaceutical firms could eventually develop standardized cannabis derived medications for pharmacy distribution, those products would exist alongside, not within, Washington’s state licensed cannabis system. Critics worry that future federal policy could increasingly favor pharmaceutical pathways over access to the whole plant.
Despite public confusion, the rescheduling announcement does not affect people currently incarcerated for marijuana related offenses. It does not clear criminal records or change sentencing laws.
“There is no effect on criminal records,” Jeter said. “Rescheduling provides for no changes in the penal system or repeal of current laws.”
For those who hoped the announcement would address racial and social disparities created by decades of marijuana enforcement, the move falls short. Jeter also warned that additional layers of regulation could introduce new risks and barriers to commercial entry.
Among plant rights activists, reaction to the announcement has been restrained. For those who advocate for personal cultivation and broader access, Schedule III offers little improvement.
“For plant freedom activists like myself, there is no particular improvement to those freedoms,” Jeter said. “Personal growing will largely be unlawful. Possession limits will continue. There will be no medical coverage for those who choose herbal medication.”
Jeter aligns herself with what she calls the “Like Tomatoes” position, arguing that cannabis should be removed entirely from the federal scheduling system.
“There is no reason why a plant with no known lethal dose should be highly regulated,” she said, “while tomatoes that are actually poisonous if misused are sold in every grocery outlet in the United States.”
From that perspective, Schedule III is seen as a compromise that delivers tax relief while reinforcing federal control. Jeter described the repeal of the 280E tax structure as “the poison pill with which we were bribed as an industry.”
For Tacoma residents, the most accurate way to frame the Schedule III announcement may be as a symbolic federal shift rather than a local transformation. It acknowledges medical value. It lowers some federal barriers to research and taxation. It does not legalize cannabis federally, alter Washington’s retail system, or resolve criminal justice concerns.
“This is a federal reframing, not a local transformation,” Jeter said.